keyword
https://read.qxmd.com/read/38717180/underpinnings-of-the-halachic-approach-to-brca-screening-and-intervention-facilitating-provider-counseling-for-observant-jewish-populations
#1
REVIEW
Chaya Greenberger, Pnina Mor
BACKGROUND: Halacha is the corpus of Jewish law which serves as a life blueprint for observant Jewish individuals. Health professionals counseling halachically observant populations at risk for breast cancer gene (BRCA) mutations should be well informed of the halachic approach to screening for BRCA mutations and subsequent interventions. AIM: To address the intersection of halacha with ethical norms and current medical evidence-based data as they relate to potential and identified BRCA mutation carriers at their various stages of decision-making...
April 28, 2024: Rambam Maimonides Medical Journal
https://read.qxmd.com/read/38716690/reducing-cathodic-drift-during-isoelectric-focusing-using-microscale-immobilized-ph-gradient-gels
#2
JOURNAL ARTICLE
Gabriela Lomeli, Amy E Herr
Microfluidic analytical tools play an important role in miniaturizing targeted proteomic assays for improved detection sensitivity, throughput, and automation. Microfluidic isoelectric focusing (IEF) can resolve proteoforms in lysate from low-to-single cell numbers. However, IEF assays often use carrier ampholytes (CAs) to establish a pH gradient for protein separation, presenting limitations like pH instability in the form of cathodic drift (migration of focused proteins toward the cathode). Immobilized pH gradient (IPG) gels reduce cathodic drift by covalently immobilizing the pH buffering components to a matrix...
May 8, 2024: Analytical Chemistry
https://read.qxmd.com/read/38715609/from-standard-therapies-to-monoclonal-antibodies-and-immune-checkpoint-inhibitors-an-update-for-reconstructive-surgeons-on-common-oncological-cases
#3
REVIEW
Leonard Knoedler, Lioba Huelsboemer, Katharina Hollmann, Michael Alfertshofer, Konstantin Herfeld, Helia Hosseini, Sam Boroumand, Viola A Stoegner, Ali-Farid Safi, Markus Perl, Samuel Knoedler, Bohdan Pomahac, Martin Kauke-Navarro
Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully incorporated into standard treatment algorithms. Such emerging therapy concepts have demonstrated improved complete remission rates and prolonged progression-free survival compared to conventional chemotherapies...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38713311/cdk4-6-inhibitors-the-devil-is-in-the-detail
#4
REVIEW
Tara Magge, Sneha Rajendran, Adam M Brufsky, Julia Foldi
PURPOSE OF REVIEW: Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer. RECENT FINDINGS: Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy...
May 7, 2024: Current Oncology Reports
https://read.qxmd.com/read/38711392/incidence-and-risk-factors-of-picc-related-thrombosis-in-breast-cancer-a-meta-analysis
#5
JOURNAL ARTICLE
Fanlun Meng, Shujun Fan, Lingmin Guo, Zhongfeng Jia, Hongjun Chang, Feng Liu
BACKGROUND: The incidence and risk factors of peripherally inserted central catheter-related thrombosis in patients with breast cancer have not been fully elucidated. METHOD: Meta-analysis was performed by searching all studies on the incidence of peripherally inserted central catheter-associated thrombosis and risk factors for its formation in breast cancer patients from the establishment of the database to May 2023, including PubMed, Embase, Web of Science, China Knowledge Network, China Biomedical Literature Service System (SinoMed) and Wanfang databases...
May 6, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38707046/from-60-to-5-in-12-weeks-a-trastuzumab-induced-left-ventricular-ejection-fraction-drop
#6
Qianjun Pan, Rui Zhao, Suzette Graham-Hill
Trastuzumab is the first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, trastuzumab is associated with cardiotoxicity. It manifests with an asymptomatic reduction of left ventricular ejection fraction (LVEF) and is reversible after discontinuation. Trastuzumab-induced new-onset acute decompensated heart failure is rare (0.5%). We report a case of a 54-year-old woman who received anthracycline (idarubicin, accumulated dose 400 mg/m2 doxorubicin equivalent) for her acute promyelocytic leukocyte 10 years ago, had no relevant comorbidities or other pre-existing cardiovascular diseases, had maintained normal cardiac function, presenting with new-onset dyspnea at rest and bilateral lower extremities swelling 12 weeks after receiving trastuzumab induction chemotherapy for her newly diagnosed early stage HER2-positive breast cancer...
April 2024: Curēus
https://read.qxmd.com/read/38706654/decision-support-for-breast-cancer-screening-decisions-a-single-case-pre-post-test-study
#7
JOURNAL ARTICLE
Mia McDonald, Dawn Stacey
Canadian guidelines recommend shared decision making for women less than 50 years old who are considering breast cancer screening. Nurses can support women in making these decisions. This single case pre-/post-test study measured change in decisional conflict after decision support for a woman less than 50 years old considering whether or not to initiate mammography screening. At baseline, a 44-year-old female at average risk of breast cancer was experiencing decisional conflict. She scored 1 out of 4 on the SURE test indicating feeling uninformed, unclear values, and inadequate support...
2024: Canadian Oncology Nursing Journal
https://read.qxmd.com/read/38705054/hormone-therapy-in-women-with-benign-breast-disease-what-little-is-known-and-suggestions-for-clinical-implementation
#8
REVIEW
Sabrina K Sahni, Jessica L Fraker, Lauren F Cornell, Christine L Klassen
Benign breast disease encompasses a spectrum of lesions within the breast. While some lesions pose no increase in risk, others may elevate the likelihood of developing breast cancer by four- to five-fold. This necessitates a personalized approach to screening and lifestyle optimization for women. The menopausal transition is a critical time for the development of benign breast lesions. Increased detection can be attributed to the heightened precision and utilization of screening mammography, with or without the use of supplemental imaging...
April 6, 2024: Maturitas
https://read.qxmd.com/read/38704740/factors-influencing-the-self-management-of-breast-cancer-related-lymphedema-a-meta-synthesis-of-qualitative-studies
#9
JOURNAL ARTICLE
Ying Wang, Tingting Wei, Miaomiao Li, Peipei Wu, Wanmin Qiang, Xian Wang, Aomei Shen
BACKGROUND: Patients with breast cancer have an estimated 14% to 60% risk of developing lymphedema after treatment. Self-management behavior strategies regarding lymphedema are essential in preventing and alleviating the severity of lymphedema. OBJECTIVE: The aim of this study was to evaluate qualitative research evidence on the potential influencing factors for self-management behaviors of lymphedema in patients with breast cancer. METHODS: A systematic search of 10 electronic databases was conducted to identify qualitative studies on patient experience of lymphedema self-management...
May 5, 2024: Cancer Nursing
https://read.qxmd.com/read/38704606/comprehensive-characterization-of-stemness-related-lncrnas-in-triple-negative-breast-cancer-identified-a-novel-prognostic-signature-related-to-treatment-outcomes-immune-landscape-analysis-and-therapeutic-guidance-a-silico-analysis-with-in-vivo-experiments
#10
JOURNAL ARTICLE
Min Zhang, Fangxu Zhang, Jianfeng Wang, Qian Liang, Weibing Zhou, Jian Liu
BACKGROUND: Cancer stem cells (CSCs) and long non-coding RNAs (lncRNAs) are known to play a crucial role in the growth, migration, recurrence, and drug resistance of tumor cells, particularly in triple-negative breast cancer (TNBC). This study aims to investigate stemness-related lncRNAs (SRlncRNAs) as potential prognostic indicators for TNBC patients. METHODS: Utilizing RNA sequencing data and corresponding clinical information from the TCGA database, and employing Weighted Gene Co-expression Network Analysis (WGCNA) on TNBC mRNAsi sourced from an online database, stemness-related genes (SRGs) and SRlncRNAs were identified...
May 4, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38704119/making-informed-choices-on-incorporating-chemoprevention-into-care-michoice-swog-1904-design-and-methods-of-a-cluster-randomized-controlled-trial
#11
JOURNAL ARTICLE
K D Crew, G L Anderson, K B Arnold, A P Stieb, J N Amenta, N Collins, C W Law, S Pruthi, A Sandoval-Leon, D Bertoni, M T Grosse Perdekamp, S Colonna, S Krisher, T King, L D Yee, T J Ballinger, C Braun-Inglis, D Mangino, K B Wisinski, C A DeYoung, M Ross, J Floyd, A Kaster, L Vander Walde, T Saphner, C Zarwan, S Lo, C Graham, A Conlin, K Yost, D Agnese, C Jernigan, D L Hershman, M L Neuhouser, B Arun, R Kukafka
INTRODUCTION: Women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) have a significantly increased risk of breast cancer, which can be substantially reduced with antiestrogen therapy for chemoprevention. However, antiestrogen therapy for breast cancer risk reduction remains underutilized. Improving knowledge about breast cancer risk and chemoprevention among high-risk patients and their healthcare providers may enhance informed decision-making about this critical breast cancer risk reduction strategy...
May 2, 2024: Contemporary Clinical Trials
https://read.qxmd.com/read/38703936/chat-epro-development-and-pilot-study-of-an-electronic-patient-reported-outcomes-system-based-on-chatgpt
#12
JOURNAL ARTICLE
Zikang Chen, Qinchuan Wang, Yaoqian Sun, Hailing Cai, Xudong Lu
OBJECTIVE: Chatbots have the potential to improve user compliance in electronic Patient-Reported Outcome (ePRO) system. Compared to rule-based chatbots, Large Language Model (LLM) offers advantages such as simplifying the development process and increasing conversational flexibility. However, there is currently a lack of practical applications of LLMs in ePRO systems. Therefore, this study utilized ChatGPT to develop the Chat-ePRO system and designed a pilot study to explore the feasibility of building an ePRO system based on LLM...
May 2, 2024: Journal of Biomedical Informatics
https://read.qxmd.com/read/38702983/what-factors-influence-the-uptake-of-bowel-breast-and-cervical-cancer-screening-an-overview-of-international-research
#13
JOURNAL ARTICLE
Sarah R Prowse, Miriam Brazzelli, Shaun Treweek
BACKGROUND: For cancer screening programmes to be effective in early detection it is important that those invited can access screening services and understand the benefits of participation. A better understanding of the factors that matter to potential participants of cancer screening programmes can assist in developing strategies to increase current uptake. METHODS: We conducted an overview of systematic reviews to answer the question: What factors influence the uptake of cancer screening services (breast, bowel and cervical) in high-income countries? A thematic approach supported by tabular summaries and qualitative heat maps was used to categorize factors, described as 'barriers' or 'facilitators'...
May 3, 2024: European Journal of Public Health
https://read.qxmd.com/read/38702555/pilot-randomized-controlled-trial-of-a-program-to-enhance-experience-and-adherence-with-adjuvant-endocrine-therapy-among-women-with-non-metastatic-breast-cancer-12-month-quantitative-results
#14
JOURNAL ARTICLE
Odilon Assan, Victoria Memoli, Laurence Guillaumie, Véronique Turcotte, Martine Lemay, Anne Dionne, Julie Lemieux, Louise Provencher, Carolyn Gotay, Marijn de Bruin, Line Guénette, Sophie Lauzier
PURPOSE: Adjuvant endocrine therapy (AET) reduces recurrence risk after hormone receptor-positive breast cancer, but non-adherence is common. We pilot-tested SOIE, a program to enhance AET experience and adherence, to assess its acceptability, feasibility, and effects on psychosocial precursors of AET adherence. METHODS: We conducted a 12-month pilot randomized controlled trial among women who had a first AET prescription. Intervention group received SOIE while control group received usual care...
May 4, 2024: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/38700760/-metastasis-in-the-periocular-region
#15
REVIEW
Yating Liu, Alexander C Rokohl, Martin R Müller, Vinodh Kakkassery, Wanlin Fan, Ludwig M Heindl
Orbital and periocular metastatic tumors used to be considered very rare; however, with the constant updating of drugs and detection methods for cancer treatment, new chemotherapies and radiation treatments are being used. The life expectancy of cancer patients has become longer and periocular metastases are becoming easier to detect. Our knowledge of this rare disease of metastases also needs to be updated. This article reviews the incidence, symptomatic presentation, clinical features, diagnostic approaches and current treatment of metastatic tumors of the orbit and ocular adnexa in these patients...
May 3, 2024: Ophthalmologie
https://read.qxmd.com/read/38700724/associations-between-subjective-social-status-and-predictors-of-interest-in-genetic-testing-among-women-diagnosed-with-breast-cancer-at-a-young-age
#16
JOURNAL ARTICLE
Jonathan N Odumegwu, Daniel Chavez-Yenter, Melody S Goodman, Kimberly A Kaphingst
PURPOSE: Genetic testing for gene mutations which elevate risk for breast cancer is particularly important for women diagnosed at a young age. Differences remain in access and utilization to testing across social groups, and research on the predictors of interest in genetic testing for women diagnosed at a young age is limited. METHODS: We examined the relationships between subjective social status (SSS) and variables previously identified as possible predictors of genetic testing, including genome sequencing knowledge, genetic worry, cancer worry, health consciousness, decision-making preferences, genetic self-efficacy, genetic-related beliefs, and subjective numeracy, among a cohort of women who were diagnosed with breast cancer at a young age...
May 3, 2024: Cancer Causes & Control: CCC
https://read.qxmd.com/read/38699790/ixabepilone-related-angiographically-silent-macular-edema
#17
JOURNAL ARTICLE
Seher Köksaldı, Mustafa Kayabaşı, Sinan Emre, Ali Osman Saatci
INTRODUCTION: We present a single-eyed case with a previous diagnosis of breast cancer who had intraretinal cystoid changes associated with the systemic administration of ixabepilone in her only seeing eye. To our best knowledge, this is the first reported case describing this phenomenon related to the ixabepilone administration. CASE DESCRIPTION: A 54-year-old woman with a history of breast cancer was examined due to visual deterioration in her only good left eye...
May 2024: European Journal of Ophthalmology
https://read.qxmd.com/read/38698386/a-stakeholder-analysis-to-prepare-for-real-world-evaluation-of-integrating-artificial-intelligent-algorithms-into-breast-screening-prep-air-study-a-qualitative-study-using-the-who-guide
#18
JOURNAL ARTICLE
Rumana Newlands, Hanne Bruhn, Magdalena Rzewuska Díaz, Gerald Lip, Lesley A Anderson, Craig Ramsay
BACKGROUND: The national breast screening programme in the United Kingdom is under pressure due to workforce shortages and having been paused during the COVID-19 pandemic. Artificial intelligence has the potential to transform how healthcare is delivered by improving care processes and patient outcomes. Research on the clinical and organisational benefits of artificial intelligence is still at an early stage, and numerous concerns have been raised around its implications, including patient safety, acceptance, and accountability for decisions...
May 2, 2024: BMC Health Services Research
https://read.qxmd.com/read/38697672/-68-ga-fap-2286-pet-of-solid-tumors-biodistribution-dosimetry-and-comparison-with-18-f-fdg
#19
JOURNAL ARTICLE
Brad Kline, Surekha Yadav, Youngho Seo, Robin Cumming Ippisch, Jessa Castillo, Rahul R Aggarwal, Robin Kate Kelley, Spencer C Behr, Robert R Flavell, Courtney Lawhn-Heath, Michelle Melisko, Hope S Rugo, Victoria Wang, Sue S Yom, Patrick Ha, Fei Jiang, Thomas A Hope
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68 Ga-FAP-2286, present the first-to our knowledge-dosimetry analysis to date, and compare the agent with 18 F-FDG and FAPI compounds. Methods: Patients were administered 219 ± 43 MBq of 68 Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool)...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38696126/emerging-toxicities-of-antibody-drug-conjugates-for-breast-cancer-clinical-prioritization-of-adverse-events-from-the-fda-adverse-event-reporting-system
#20
JOURNAL ARTICLE
Sara Cecco, Stefano Puligheddu, Michele Fusaroli, Lorenzo Gerratana, Miao Yan, Claudio Zamagni, Fabrizio De Ponti, Emanuel Raschi
BACKGROUND: Antibody-drug conjugates (ADCs) are gaining widespread use in the treatment of breast cancer, although toxicity remains an underexplored issue in the real-world clinical setting. Individual case safety reports collected in large pharmacovigilance databases can advance our knowledge on their safety profile in routine clinical practice. OBJECTIVE: We prioritized adverse events (AEs) reported with ADCs approved for breast cancer using the Food and Drug Administration Adverse Event Reporting System (FAERS)...
May 2, 2024: Targeted Oncology
keyword
keyword
72646
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.